Sign in with GoogleDesmoteplase
What is Desmoteplase?
Desmoteplase is a novel, highly fibrin-specific thrombolytic agent in phase III of clinical development. In 2009, two large trials (DIAS-3 and DIAS-4) were started, and the results of these studies will determine whether desmoteplase will gain marketing authorization as a safe and effective treatment for patients with acute ischaemic stroke. Filing with health authorities is estimated in the second quarter of 2014. The Danish pharmaceutical company, H. Lundbeck A/S (commonly known as Lundbeck), owns the worldwide rights to desmoteplase.
Questions and answers on "Desmoteplase"
Mrs Smith is 82 years old and lives in her own home. She receives assistance
with physical chores such as shopping and cleaning, but is still able...
MD Dear Sir/ Madam
Thanks for your query.
1. The history given is suggestive of TIA (transient ischemic attack) of possibly posterior circulation.
2....